News
10d
Cryptopolitan on MSNMEI Pharma's Litecoin treasury purchase sets off LTC rally
MEI Pharma announced its first LTC purchase, sparking a rally for one of the oldest and well-established crypto coins.
One day after MEI Pharma rejected an unsolicited bid from investors Anson Funds Management and Cable Car Capital to take the company private, CEO Daniel P. Gold, PhD left effective immediately. Gold, ...
San Diego-based MEI Pharma (NASDAQ:MEIP) has acquired 929,548 Litecoin (CRYPTO: LTC) tokens, becoming the first U.S.-listed ...
MEI Pharma, Inc. is a pharmaceutical company specializing in the development of innovative cancer therapies, focusing on acquiring and advancing promising cancer agents through strategic ...
MEI Pharma may already have a merger lined up with Infinity Pharmaceuticals, but another suitor has emerged from the fray. MEI Pharma announced Tuesday evening it has received a proposal from ...
MEI Pharma Inc has a consensus price target of $22.27 based on the ratings of 7 analysts. The high is $80 issued by Brookline Capital on May 23, 2023. The low is $0.1 issued by Jefferies on ...
MEI Pharma's clinical development pipeline also includes ME-401, a highly differentiated oral PI3K delta inhibitor currently in a Phase Ib study in patients with relapsed/refractory CLL or ...
MEI Pharma, Inc. David A. Walsey Tel: 858-369-7104 [email protected] Jason I. Spark Canale Communications for MEI Tel: 619-849-6005 [email protected] Kyowa Kirin Co., Ltd.: Hiroki ...
One stock that might be an intriguing choice for investors right now is MEI Pharma, Inc. MEIP. This is because this security in the Medical - Drugs space is seeing solid earnings estimate revision ...
MEI Pharma, Inc. MEIP was a big mover last session, as the company saw its shares rise more than 8% on the day. The move came on solid volume too with far more shares changing hands than in a ...
MEI Pharma Conference Call and Webcast MEI will host an investor and analyst webcast event today, November 30, 2021, at 8:00 AM Eastern Time to review the TIDAL phase 2 study data reported today ...
MEI Pharma had cash and cash equivalents of $36.2 million as of March 31, 2018. It was anticipating at first that its cash would be enough until the 1st half of its calendar 2019.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results